Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Oxycodone · Oxycodone Hydrochloride, Roxicodone

Small molecule · Agonist of mu-opioid receptor (OPRM1) · developed by Roxane

Approved FDA, Oct 1998
4 Registered trials

What is Oxycodone?

Oxycodone is a semi-synthetic, morphine-like opioid that binds relatively selectively to mu-opioid receptors in the central nervous system, mimicking endogenous opioids. It is studied in chronic low back pain, chronic pain, opioid use, and recreational drug use, and has been studied in opioid exposure after cesarean section.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Oxycodone Hydrochloride, Roxicodone, Opioid Exposure
Drug type
Small molecule
Targets
mu-opioid receptor (OPRM1)
Mechanism
Agonist of mu-opioid receptor (OPRM1)
Pathways
G-protein signaling, adenylate cyclase inhibition, cAMP reduction, neurotransmitter release inhibition, calcium channel closure
Therapy area
Neurology, Oncology
Developer
Roxane
In trials of
COLL, ENSC, GRCE
FDA status
Approved as Oxycodone Hydrochloride, Roxicodone (October 26, 1998), NDA020932

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03588806 Phase 4 Chronic Pain Terminated COLL
NCT01685684 Phase 3 Chronic Low Back Pain Completed COLL
NCT05567354 Phase 1 Recreational Drug Use Completed ENSC
NCT05280743 N/A Cesarean Section Complications Completed GRCE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cesarean Section ComplicationsChronic Low Back PainChronic PainDeglutitionOpioid UseRecreational Drug Use

Other drugs acting on OPRM1

Methadone FDA approved Morphine FDA approved Nalbuphine FDA approved Naloxone FDA approved Naltrexone FDA approved PF614 Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.